Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.

摘要: Antiphospholipid antibodies (aPL) characterize patients at risk for both arterial and venous thrombotic complications. Recently it has been recognized that the presence of plasma proteins such as beta 2-glycoprotein I(beta 2 GPI) prothrombin are essential binding aPL to phospholipids these probably real target aPL. The discovery new antigens introduces possibility assays detect However, is not known whether improve identification thrombosis. In this retrospective study we compared value classic LAC (lupus anticoagulant) ACA (anticardiolipin antibodies) associated with complications, which based on 2GPI. To do so, have used in a group 175 SLE correlated positivity different history Control groups were without but and/or thrombosis (n = 23), 40) 42 healthy controls. univariate analysis, no distinction made between high low antibody levels, confirmed be related Anti-beta 2GPI- anti-prothrombin-antibodies, IgG IgM correlate anti-beta 2GPI-IgM Multivariate analysis showed strongest factor (OR 9.77; 95% CI 1.74-31.15) None other factors significant additional factor. For 6.55; 2.36-18.17), ACA-IgM above 20 MPL units also appeared (p 0.0159) 3.90; 1.29-11.80). Furthermore, anti-prothrombin-antibodies positive 60) does increase results (i) assay correlates best (ii) neither 2GPI ELISA nor anti-prothrombin gives information patients.